Zobrazeno 1 - 10
of 326
pro vyhledávání: ''
Autor:
Junji Uchino, Akira Nakao, Osamu Hiranuma, Yusuke Chihara, Masahiro Iwasaku, Takashi Kijima, Chieko Takumi, Yoshiko Kaneko, Takahiro Yamada, Masafumi Takeshita, Makoto Hibino, Yoshie Morimoto, Koichi Takayama, Kenji Morimoto, Takayuki Takeda, Tadaaki Yamada, Yasuhiro Goto, Hiroyuki Yamaguchi, Takashi Yokoi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 161
Combination therapy of immune checkpoint inhibitors and chemotherapy is considered to be one of the standard treatment options for patients with advanced non-small-cell lung cancer (NSCLC). However, the clinical significance of immune checkpoint inhi
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 150
Large cell neuroendocrine carcinoma (LCNEC) is a rare pulmonary malignancy with clinicopathologic features of both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Given the paucity of available data regarding LCNEC management, w
Publikováno v:
Lung Cancer
Lung Cancer, Elsevier, 2020, 145, pp.71-75. ⟨10.1016/j.lungcan.2020.04.025⟩
Lung Cancer, Elsevier, 2020, 145, pp.71-75. ⟨10.1016/j.lungcan.2020.04.025⟩
Immunotherapy with immune checkpoint inhibitors (ICIs) represents a breakthrough in lung cancer treatment. The efficacy of monoclonal antibodies targeting the programmed cell death protein 1 (PD-1), its ligand L1 (PD-L1), and cytotoxic T-lymphocyte-a
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 143
Introduction Several obstacles may delay receipt of targeted treatment in patients with anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC). This study examined the factors associated with delayed initiation of ALK inhibitor
Autor:
Matteo Giaj Levra, V. Grumberg, Anne-Françoise Gaudin, John R. Penrod, Jean-Baptiste Assié, Christos Chouaid, François-Emery Cotté, Ronan Jolivel, B. Jouaneton, C. Calvet, Romain Corre
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 140
Objectives Nivolumab is now a reference treatment for patients with advanced non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy. Little data are available on treatment approaches following discontinuation of nivolum
Autor:
Kaiyan Chen, Xiaoqing Yu, Zhiyu Huang, Yun Fan, Guoping Cheng, Yanjun Xu, Fanrong Zhang, Guanxia Zhu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 142
The efficacy of immunotherapy in epidermal growth factor receptor (EGFR)-activating non-small cell lung cancer (NSCLC) is limited. However, a series of patients with uncommon EGFR alterations was reported to derive clinical benefit from PD-1 blockade
Autor:
Hui Sun, Chao Zhao, Wei Li, Xiaoxia Chen, Caicun Zhou, Chunyan Wang, Shuo Yang, Fengying Wu, Yayi He, Xuefei Li, Yiwei Liu, Shiqi Mao, Yingying Pan, Shengxiang Ren, Xiaofei Yu, Chunxia Su, Qian Liu, Yan Wang, Anwen Xiong, Guanghui Gao, Bin Chen
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of targeted therapy. This study aimed to investigate the incidence of acquired T790M mut
Autor:
Yin Shi, Youwen Zhu, Dong Ding, Shan Zeng, David P. Carbone, Longjiang She, Linli Yao, Liangfang Shen, Xuefeng Xia, Mengting Liao, Huabin Hu, Jin Huang
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 138
Objective The purpose of this study was to estimate the cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advance or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1
Autor:
P. Romanelli, Marta Scorsetti, Andrei Fodor, Giovanni Ivaldi, Olga Oneta, Barbara Alicja Jereczek-Fossa, Isa Bossi Zanetti, G. Catalano, Stefano Maria Magrini, Michela Buglione, Giancarlo Beltramo, Paolo Antognoni, Nadia Di Muzio, Marianna Alessandra Gerardi, Davide Tomasini, Antonio Laudati, Paolo Borghetti, Davide Franceschini, Marco Lorenzo Bonù, Ciro Franzese, Italo Dell'Oca
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 141
Objectives: stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) are a therapeutic option for Oligometastatic/Oligoprogressive (OM/OP) NSCLC. This retrospective multicentre analysis aims to analyse clinical outcomes and t
Autor:
Ye Li, Lin Wu, Qian Chu, Zheng-Bo Han, Gen Lin, Wen-Zhao Zhong, Yi-Long Wu, Fan Yang, Bo Zhu, Hong-Mei Zhang, Jinliang Wang, Jie Hu, Meng-Xia Li, Jia-Tao Zhang, Li-Xu Yan, Huijuan Wang, Zhengfei Zhu, Xiao-Rong Dong, C. Xu, Zhengbo Song, Jie Lin, Zong-Yang Yu
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Objectives The 2015 World Health Organization classification defines pulmonary large-cell neuroendocrine carcinoma (LCNEC) as a high-grade neuroendocrine carcinoma. However, the clinical characteristics and prognostic factors of pure LCNEC and combin